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Abstract
Background: The diagnosis of malignant hematologic diseases has become increasingly complex during the last decade. It
is based on the interpretation of results from different laboratory analyses, which range from microscopy to gene expression
profiling. Recently, a method for the analysis of RNA phenotypes has been developed, the nCounter technology
(NanostringH Technologies), which allows for simultaneous quantification of hundreds of RNA molecules in biological
samples. We evaluated this technique in a Swiss multi-center study on eighty-six samples from acute leukemia patients.
Methods: mRNA and protein profiles were established for normal peripheral blood and bone marrow samples. Signal
intensities of the various tested antigens with surface expression were similar to those found in previously performed
Affymetrix microarray analyses. Acute leukemia samples were analyzed for a set of twenty-two validated antigens and the
Pearson Correlation Coefficient for nCounter and flow cytometry results was calculated.
Results: Highly significant values between 0.40 and 0.97 were found for the twenty-two antigens tested. A second
correlation analysis performed on a per sample basis resulted in concordant results between flow cytometry and nCounter
in 44–100% of the antigens tested (mean= 76%), depending on the number of blasts present in a sample, the homogeneity
of the blast population, and the type of leukemia (AML or ALL).
Conclusions: The nCounter technology allows for fast and easy depiction of a mRNA profile from hematologic samples. This
technology has the potential to become a valuable tool for the diagnosis of acute leukemias, in addition to multi-color flow
cytometry.
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Introduction
Diagnosis of leukemia and lymphoma is in part based on the
recognition of surface antigens expressed by the tumor cells. So
far, over 360 hematopoietic membrane markers have been
classified as ‘‘clusters of differentiation’’ (CD), and the study of
various combinations of these antigens by flow cytometry is used in
the work-up of patients with a suspected hematologic neoplasia. In
practice, routine flow cytometry laboratories use specific anti-
bodies against only 30–50 of the known antigens for the
differential diagnosis of leukemias and lymphomas. The extent
of the panels used depends on the laboratories expertise, its
resources and the costs of these analyses, which become
increasingly expensive and time-consuming the more antibodies
are used.
Several other methods are currently being developed, which,
like flow cytometry, allow the study of a set of simultaneously
expressed protein antigens. Mass cytometry, a new technology
based on atomic mass spectrometry, offers the possibility to
analyze literally hundreds of different surface antigens in one
single assay [1]. Proof of principle of this technology in
leukemia diagnosis has already been reported [2]. Another
approach uses antibody microarrays based on a solid phase cell-
capture technique [3], [4]. Belov L et al. reported the analysis
of the simultaneous expression of eighty-two antigens in 733
patients with a variety of leukemias and lymphomas, achieving
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a high degree of diagnostic consensus between established
criteria and the results of an antibody microarray (93.9% for
peripheral blood and 97.6% for bone marrow aspirates) [3].
Although this approach potentially offers the possibility to
analyze in parallel several hundreds of antigens, the drawbacks
are the limitation to surface proteins and the rather low
sensitivity, since more than 20% of blasts have to be present in
a sample in order to recognize its malignant signature. Other
methods of protein phenotyping have, to our knowledge, not yet
reached the clinical practice.
An alternative approach for the analysis of the biological state of
a cell lies in the analysis of its mRNA profile. Indeed, as protein
profiling, methods of mRNA profiling (gene expression profiling,
GEP) using microarray technology have been developed in the last
decade and have been already extensively validated in the field of
lymphoma and leukemia diagnosis [5], [6]. Recently, the company
Nanostring has developed a new high-throughput RNA expression
profiling system (nCounter), which allows the direct digital readout
of mRNA molecules and their relative abundance using small
amounts of total RNA (100 ng), without requiring cDNA synthesis
or enzymatic reactions [7]. Several groups have already compared
the nCounter method, the Affymetrix platform, and standard
quantitative RT-PCR, and observed high correlation coefficients
above 0.9 for values obtained by any of the three methods [7], [8],
[9], [10].
So far, only a few studies have attempted to correlate the
findings of both types of approaches, of protein and of mRNA
expression analysis. Kern et al. compared data from flow
cytometry and mRNA-microarrays on thirty-six antigens from
814 patient samples. They found heterogeneous correlation
coefficients between the two techniques, ranging from rather low
to high correlation coefficients for certain antigens (e.g. 0.17 for
CD19 and 0.80 for CD34, respectively) [11].
We performed the present study with the aim to validate the
nCounter technology for the diagnosis of acute leukemias, by
comparing mRNA profiles obtained by this methodology to
protein profiles obtained by flow cytometry. We studied eighty-
six samples from acute leukemia patients in a multi-center study
and found high correlation for most antigens relevant in routine
flow cytometric analyses (corr. coeff. from 0.40 for CD38 to
0.97 for CD133). We therefore propose this system as a new,
extremely easy to use, rapid, and very informative method of
analysis for the diagnosis of acute leukemias and other
hematologic diseases.
Results
Validating the nCounter Probe Set
In order to investigate potential correlations between mRNA
and protein expression in peripheral blood (PB) and bone marrow
(BM) samples we choose a set of eighty-eight well-known antigens,
most of them currently used for leukemia diagnosis in routine flow
cytometry laboratories. Information about these antigens, in
particular their expression profile in different cell populations
present in PB and BM, was readily available from the literature
and public databases (www.genecards.org; http://prow.nci.nih.
gov).
With custom-designed probes from Nanostring specific for these
eighty-eight antigens we first analyzed seven different, highly
purified, cell populations, sorted from peripheral blood (CD4+ T-
cells, CD8+ T-cells, NK cells, CD19+ B-cells, CD14+ monocytes,
CD33+ granulocytes, eosinophils). As example, probes for genes
expressed solely by B cells, gave high signals in the sample with the
purified B cell population and weak signals in the other six sorted
populations containing only a few contaminating B cells (Figure 1).
As expected, differences were in the 2- to 3-log range, depending
on the probe and its specificity, the amount of mRNA/B cell, and
the number of contaminating B cells in the other sorted cell
samples. For other cell-type specific genes results were similar (data
not shown).
mRNA Expression Profiles in Normal Peripheral Blood and
Normal Bone Marrow Samples
Cell lysates from eleven normal BM aspirates and from PB from
five blood donors were analyzed with the nCounter. Means for
signal intensities were calculated and ordered according to signal
intensity and specific expression in the different cell subpopula-
tions, e.g. T cells, B cells, etc. (Table S1). mRNA quantities for
several cell-type specific genes varied between BM and PB,
depending on the number of cells from a subpopulation present in
one or the other of these two compartments, on their differenti-
ation stage, and on the number of mRNA molecules/cell. For
example, genes specific for blast cells were expressed essentially in
normal BM, but not in PB samples (CD34 was increased 32-fold
compared to PB, CD133 185-fold, and CD117 12-fold), whereas
T-cell specific genes were found increased 9.5-fold 62.9 in PB
compared to BM, in accordance with the 2- to 3-fold higher
number of T cells in PB.
Comparison of mRNA and Protein Phenotypes
Twenty-two antigens with a particular relevance in flow
cytometric diagnosis and used by most laboratories taking part
in the study were chosen for a comparative analysis by flow
cytometry and the nCounter technology.
This analysis was performed for seventy-three cases: normal
bone marrow (11 samples), normal peripheral blood (5 samples),
sorted cell populations (CD4+ T cells, CD8+ T cells, B cells,
CD34+ blasts, monocytes, neutrophils, eosinophils and erythroid
precursors), and acute leukemia patients (45 samples), CLL
patients (2 samples), and CML patients (2 samples) (Table S2).
This resulted in a total of 1606 comparisons.
The comparisons between signal intensities obtained by the
nCounter analysis and percentages of positive cells as determined
by flow cytometry using isotype controls resulted in highly
significant correlations for all the genes analyzed. Figure 2A shows
the results for four antigens: CD34, CD19, CD7, and CD13.
Using Pearson’s correlation the coefficients ranged between 0.40
and 0.97 (Table 1).
In addition, MFI values obtained from flow cytometry analysis
were compared with the results from the nCounter. As shown in
Table S3, the correlation between these two measurements was -
for most antigens tested - quite similar to the correlation between
percentage of positive cells and nCounter values. But for several
antigens (e.g.: HLA, CD11b) the correlation coefficients were
lower, probably relating to the fact that antibodies coupled to
different fluorochromes were used in different patient samples for
the detection of these antigens.
Analysis of Leukemia Patients
For several antigens we then analyzed the correlation between
% of blast cells in a given sample and nCounter signals. As shown
in Figure 2B, samples with blasts, which did not express or only
partially expressed CD34, were clearly distinct from samples with
CD34 positive blasts. In the case of CD19, all samples of B-ALL
showed values for CD19, which were clearly above the values for
normal bone marrow, as were values for CLL or for the samples
with blasts of mixed phenotype acute leukemia (MPAL).
Digital RNA Counting for Acute Leukemia Diagnosis
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To analyze in more detail the sensitivity of the nCounter
method we performed a spiking experiment, in which we diluted
a leukemia sample in a normal bone marrow sample (Table S4).
Depending on the background mRNA counts for a given antigen
present in the normal bone marrow sample, the nCounter was
able to discriminate a diluted sample with as few as 3% blasts from
the normal sample (e.g.: CD19, CD22, CD34). This high
sensitivity was restricted to antigens with low background mRNA
counts in normal samples; for other antigens with high background
mRNA counts the sensitivity was much less (e.g. for CD58 only
samples with .50% blasts could be discriminated from normal
samples). The sensitivity thresholds for CD34, CD19, CD7, and
CD13 can also be inferred from Figure 2.
For each leukemia patient the protein phenotype of the
malignant blast population was determined using flow cytometry
and compared to the mRNA phenotype obtained with the
nCounter analysis. Two different cut-offs were used in order to
consider a signal from the nCounter as ‘‘positive’’: (A) the ratio of
the signal in the leukemia sample/mean of the signal in the normal
BM or peripheral blood sample, respectively, had to be $2 and,
(B) the signal in the sample had to be higher than the mean of the
normal BM or peripheral blood sample value +2 SD (Figure 3A).
Signals fulfilling both criteria were interpreted as proof for the
presence of the corresponding mRNA in the blast population.
Comparing results from flow cytometry and nCounter analyses
showed that, depending on the leukemia sample analyzed, the
measurements by the two methods corresponded in 44–100% of
the antigens studied (mean= 76%; Table S5). Table 2 shows the
correlation coefficient expressed separately for each antigen
studied. When the concordance between the two methods is
expressed for all antigens studied depending on the % of blasts
present in the sample, a mean correlation coefficient of 0.63 was
found (Figure 3B).
A typical example of the type of analysis we obtained by our
analysis is shown in Figure 4 for a case of B-ALL with 87% blasts.
Of fifteen antigens studied by flow cytometry, seven were
expressed by the blasts. With the nCounter we studied eighty-
eight antigens and found RNAs of nineteen of them expressed by
the blasts, including six out of the seven antigens found to be
positive by flow cytometry ( = concordance of 86%).
Discrepancies were observed in the following situations (Table
S5):
(A) Flow cytometry results showed no protein expression on the
blast cell surface, whereas the results from the nCounter
were clearly positive (25% of discordant cases). This
situation was encountered essentially for CD15 and
CD56. Most probably, in these cases translation from
mRNA to protein in the malignant blasts was defective and
led to absence of the protein on the cell surface.
Alternatively, the antibodies used for flow cytometry were
not optimal.
(B) Flow cytometry results showed positive blasts, whereas the
results from the nCounter were negative (75% of discordant
cases). This situation occurred essentially for the myeloid
genes CD13 and CD33 with correlation coefficients of 0.26
and 0.40, respectively (Table 2), and to a lesser extent for
MPO, CD11b, and CD36. In fact, as the majority of the
cells in normal PB and BM already express myeloid genes, it
becomes impossible to distinguish samples with low or
medium blast populations expressing myeloid genes from
normal samples only on the basis of total mRNA quantity.
Alternatively, leukemic blasts may have expressed only low
amounts of a certain mRNA, which made a distinction from
normal samples impossible.
Analysis of Samples from other Swiss Centers
PB and/or BM samples from forty-three leukemia patients
(Table S2) were analyzed by flow cytometry in six other Swiss
centers (Aarau, Basel, Bellinzona, Bern, Lausanne, Sion), and
leftover material was sent to Geneva where it was subsequently
studied for mRNA expression by the nCounter technique. Two
cases had to be discarded because of degraded material.
Comparing results from flow cytometry and nCounter analyses
for the remaining forty-one samples showed that, similarly to
samples from Geneva, the two methods corresponded in 52–100%
of the antigens studied (mean= 77%). Correlations were superior
in ALL samples compared to AML samples, with mean
correlations of 88% and 72%, respectively (Table S6).
The results of the nCounter analysis of these samples, as well as
of the 45 cases from Geneva, and normal BM and PB samples are
shown in table S7 and as a heatmap in figure S1.
Figure 1. Analysis of mRNA expression of thirteen B cell specific antigens in seven different cell populations isolated from
peripheral blood. For each antigen the columns from left to right correspond to CD4+ T-cells (dark gray), CD8+ T-cells (light gray), NK cells (white),
CD19+ B-cells (black), CD14+ monocytes (light gray), CD33+ neutrophils (gray), and eosinophils (dark grey).
doi:10.1371/journal.pone.0049010.g001
Digital RNA Counting for Acute Leukemia Diagnosis
PLOS ONE | www.plosone.org 3 November 2012 | Volume 7 | Issue 11 | e49010
Digital RNA Counting for Acute Leukemia Diagnosis
PLOS ONE | www.plosone.org 4 November 2012 | Volume 7 | Issue 11 | e49010
Discussion
Analyzing quantitatively and in parallel the expression of
hundreds of different mRNAs of a given biological sample results
in a wealth of information about the type of cells present, their
functional status, as well as their malignant or normal nature.
In the present study we compared the expression of mRNAs
coding for cell surface antigens with the expression of the
corresponding proteins in hematological samples from peripheral
blood and from bone marrow. We used the well-established flow
cytometric technique for surface protein detection and the newly
developed Nanostring technology for the mRNA determinations.
Our results show excellent correlation coefficients for most of the
antigens studied, thus demonstrating the comparability of both
methodologically different approaches (Table 1).
Various factors might influence the degree of concordance,
either at the level of mRNA detection (i.e.: number of mRNA
molecules/cell for a given antigen as well as mRNA stability,
amount of RNAse present in samples), or at the level of flow
cytometry (e.g. quality of antibodies used, leading sometimes to
nonspecific binding and overestimation of results). As our
comparisons were performed on heterogeneous samples corre-
sponding to mixtures of normal and/or malignant cell popula-
tions, differences in pre- (e.g. splice variants, mutations) or post-
translational modifications between these cells might in some cases
also explain weaker correlations between protein and mRNA
expressions.
For most of the antigens tested comparing percentage of positive
cells to nCounter values resulted in slightly higher correlation
coefficients than comparing MFI values (Table S3). This reflects
the greater variability in MFI measurements, which are due to the
technical particularities of the flow cytometric analysis (e.g.:
different antibody clones and fluorochromes result in different
MFI values for the same antigen).
Our results are in line with previous similar studies, which have
already investigated mRNA/protein correlations. Kern et al used
gene expression profiles from standard gene expression profiling
techniques (Affymetrix microarrays) and compared those to results
from flow cytometry [11]. In a total of 21581 comparisons
performed on thirty-six antigens, they found correlation coeffi-
cients ranging from 0.17 to 0.81. These coefficients were
significantly lower than the ones obtained in our study (0.40 to
0.90). This very likely reflects the overall greater precision in RNA
quantification by the nCounter exploited in our study as compared
to the microarrays technologies used in the other studies (Table
S8).
The emphasis of our study was on evaluating the potential of the
nCounter technology for its application in acute leukemia
diagnosis. Whereas in flow cytometry diagnosis is based on
a multi-parameter analysis at the single cell level, the nCounter
technology measures gene expression from the total unsorted cell
population of a sample. It can therefore not substitute flow
cytometry.
In order to be informative the signals from the nCounter have
to clearly distinguish pathologic from normal samples. Using two
different algorithms we defined nCounter signals as positive and as
expressed by the blast population in a given sample. Applying this
strategy, we found concordance in 44–100% of the antigens
studied, depending on the number of blasts present in a sample as
well as on the type of leukemia. Concordance up to 100% was
seen mainly in B- and T-ALL samples with high blast numbers, as
well as in some rare forms of leukemia (e.g. AML M7, leukemic
blastic plasmacytoid dendritic cell neoplasm), corresponding to
situations in which the normal counterpart of the malignant blast
population constituted only a minor fraction of the total bone
marrow or peripheral blood cell population (Tables S5 and S6). In
these cases samples with $10% of blasts were clearly distinguished
from normal cases with ,2% blast cells (Figure 2A and 2B) and
concordance between protein and mRNA expressions was high.
For leukemias with aberrant myeloid cells concordance was lower,
in particular for the myeloid antigens CD13 and CD33 (Table 2).
Figure 2. Correlation of flow cytometric and nCounter results. A: Correlation between results from the nCounter technology and flow
cytometry for four typical antigens. Flow cytometric results are given as percentage of cells positive for a given antigen, and nCounter results as
digital counts (after normalization and background subtraction). The number of depicted data points varies depending on the antigen tested and on
the availability of both cytometric and nCounter values for a given sample. Only samples for which both values were measured are shown. Some
samples, particularly informative for a particular antigen, were highlighted with dots in different shades and patterns. nBM, normal bone marrow; corr
coeff, Pearson’s correlation coefficient. corr coeff .0.393 are statistically significant with p,0.01. B: Correlation between % of leukemic blasts as
determined by flow cytometry, and nCounter values for two typical antigens (CD34, CD19).
doi:10.1371/journal.pone.0049010.g002
Table 1. Correlation coefficient for flow cytometry (protein)
and nCounter (mRNA) values from 22 antigens.
Antigens corr coeff
CD133 0.97
CD3 0.94
CD20 0.89
TDT 0.89
CD19 0.83
CD34 0.82
CD10 0.81
CD56 0.80
CD11b 0.78
HLA-DR 0.76
CD7 0.76
CD117 0.75
CD16 0.74
CD4 0.68
CD13 0.61
CD36 0.57
CD14 0.56
MPO 0.53
CD123 0.53
CD33 0.49
CD15 0.41
CD38 0.40
Pearson’s correlation coefficient between nCounter signal intensity and
percentage of positive cells measured by flow cytometry. Twenty-two different
antigens were analyzed in seventy-three samples (11 normal bone marrow, 5
normal peripheral blood, 8 sorted cell populations, 45 acute leukemia, 2 CLL,
and 2 CML).
corr coeff .0.302 are statistically significant with p,0.01.
doi:10.1371/journal.pone.0049010.t001
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In order to show the potential utility of the nCounter technology
for multi-center studies, patients were tested first by flow cytometry
in six different Swiss centers and leftover samples were then
centrally analyzed in Geneva with the nCounter. The concor-
dance between protein and mRNA expressions (mean= 75%) was
practically as high as the concordance for the Geneva samples
(mean=76%). We expect improvement in concordance if special
pre-analytical precautions for the send-out of the samples are
taken (e.g. PAX Gene tubes to inhibit mRNA degradation), or if
flow cytometry procedures are standardized. From a practical
point of view, the ease-of-use of this technology, the short
turnaround time of typically less than two days, as well as the
possibility to use crude cell lysates for the mRNA profiling offers
immense advantages compared to previously used approaches of
mRNA analysis [12].
In summary, our study shows a high correlation between the
expression of surface proteins and of mRNA in peripheral blood or
bone marrow samples, using the well-established flow cytometry
and the newly developed nCounter technology, respectively. The
‘‘CD antigen profile’’ obtained by the nCounter is easily extend-
able to several hundreds of antigens, which can be tested in one
single assay and can thus supplement for antigens for which
routine flow cytometry laboratories do not have the necessary
antibodies available. Furthermore, extension of the antigen profile,
potentially picking up aberrant expression of several antigens
simultaneously, could compensate in some cases for the lack of
a gating strategy by flow cytometry. In a similar way a large
antigen profile could become particularly useful for the de-
termination of the exact phenotype of mixed lineage acute
leukemias (MPAL) and for the diagnosis of rare types of acute
leukemias.
Materials and Methods
Samples
Fresh peripheral blood (PB) and bone marrow (BM) samples
were obtained from patients of the Geneva Hematology Service in
accordance with institutional guidelines and after approval of the
ethical committee of the Geneva University Hospital (Table S2).
Written informed consent was obtained from all patients. Normal
blood samples were obtained from blood donors of the regional
blood transfusion center. CD14+ monocytes, CD8+ T cells,
CD56+ NK cells, CD19+ B cells, neutrophils, and eosinophils
were isolated from these samples using Enrichment and Selection
Kits from Stemcell Technologies, according to manufacturer’s
instructions. CD4+ T cells were isolated from the monocytes-
depleted fraction (obtained during the monocytes isolation) using
the EasySepH Human CD4 Positive Selection Kit (Stemcell
Technologies). Purity of the isolated cell populations was verified
by flow cytometry with specific antibodies and was .80% in all
cases (data not shown).
From each sample (PB, BM, or enriched cell populations)
106 cells were lysed in RNA lysis buffer (Qiagen, Venlo, Nether-
lands) and stored at 280uC for further analysis.
Samples from other Centers
From other Swiss Centers (Aarau, Basel, Bellinzona, Bern,
Lausanne, Sion) leftover samples from the flow cytometric analysis
of forty-three leukemic patients were obtained after approval of
the respective ethical committees (ethical committee of Kantons-
spital Aarau, ethical committee of Inselspital Bern, ethical
committee of University Hospital Lausanne, ethical committee
of Institut Central des Hoˆpitaux Valaisans, ethical Committee of
Istituto Oncologico della Svizzera Italiana) and were sent to
Geneva by mail, which took one to two days (Table S2). Written
informed consent was obtained from all patients. At arrival, the
samples were centrifuged over a Ficoll-Gradient to remove
apoptotic and dead cells, and the number of leukemic blasts was
determined by flow cytometry using a standard 5-color tube
(CD7/CD19/CD33/CD34/CD45). The samples were then
stored for further analysis at 280uC.
Flow Cytometry
Flow cytometric analysis was performed with monoclonal 5-
color antibody panels (Table S9A). In short, samples were
incubated for 15 min at RT with the corresponding antibodies,
a lysis solution (OptilyseHC, Beckman Coulter, Miami, FL) was
added for 10 min to lyse red bood cells, the cells were washed
twice, and than analyzed on a FC500 flow cytometer (Beckman
Figure 3. Comparative analysis of leukemia patients. A: Comparison of nCounter values from normal BM ( = the mean of the values from
eleven normal BM samples) with a sample from a patient with acute myeloid leukemia. Values in the acute leukemia sample, which were above the
normal BM mean +2SD, were considered positive (light rectangles) and the corresponding mRNA expressed by the leukemic blasts. B: Correlation
between % of blasts present in a leukemic sample and concordance between flow cytometry and nCounter results in forty-six patients.
doi:10.1371/journal.pone.0049010.g003
Table 2. Analysis of leukemic blasts: correlation between
results from flow cytometry and nCounter analysis for twenty-
two different antigens, each studied in forty-five leukemia
patients.
Antigens corr coeff
CD19 0.98
CD34 0.98
CD16 0.97
CD10 0.91
CD20 0.91
CD14 0.90
TDT 0.90
CD133 0.89
CD117 0.88
CD7 0.85
CD3 0.80
CD38 0.80
CD4 0.79
HLA-DR 0.79
MPO 0.78
CD11b 0.76
CD56 0.73
CD123 0.73
CD36 0.63
CD15 0.59
CD33 0.40
CD13 0.26
corr coeff .0.372 are statistically significant with p,0.01.
doi:10.1371/journal.pone.0049010.t002
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Figure 4. A typical case of B-ALL analyzed in parallel by flow cytometry and by the nCounter technique. Flow cytometry shows the
blast population being CD34pos, CD19pos, cy CD79a pos, cy IgM pos, TDT pos, CD10 pos and CD45 pos. In red: antigens found positive with both
methods.
Digital RNA Counting for Acute Leukemia Diagnosis
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Coulter). White blood cell populations were analyzed after gating
out debris, cell aggregates, dead cells, platelets and red blood cells
on FSC/SSC and CD45/SSC dotblots. Analysis of list-mode files
was performed using the FACSExpress software (De Novo
Software; Los Angeles; CA) with the analysis gate set in the
CD45/side-scatter (SSC) - plot to include all nucleated cells (i.e.:
lymphocytes, monocytes, myeloid cells and blasts). The percentage
of different cell-subpopulations was determined using anti-CD4
and anti-CD8 antibodies for T lymphocytes, anti-CD19 for B
lymphocytes, anti-CD14 for monocytes, and the CD45/SSC
pattern for myeloid cells. The percentage of blasts was determined,
using either a combination of CD45 dim/SSC low pattern and
anti-CD34, anti-CD117 or anti-CD133 antibodies for myeloid
blasts or anti-CD19 or anti-CD7 antibodies for B and T lymphoid
blasts, respectively. For each antigen analyzed the percentage of
positive cells was determined in relation to isotype controls, which
were set arbitrarily at 1% positivity. The mean fluorescent
intensity (MFI) for each antigen was determined as the ratio of
the antigen values and the isotype control value.
mRNA Analysis
The RNA from the equivalent of 104 cells (corresponding to
100–300 ng total RNA) was used for the analysis with the
nCounter system, according to the manufacturer’s protocol
(Nanostring H Technologies, Seattle, WA, USA). In brief, 4 ul of
cell lysate (in RLT buffer, according to Qiagen recommendations)
was hybridized at 65uC over night with the Nanostring Codeset.
Probes for the analysis of ninety-six different antigens (Table
S9B) were synthesized by Nanostring technologies, including
probes for seventy-six surface antigens, twelve intracellular
antigens, and eight normalization genes (Table S10). After probe
hybridizations and Nanostring nCounter digital reading, counts
for each RNA species were extracted, analyzed using a homemade
Excel macro, and then expressed as counts (molecules of mRNA/
sample) [8]. The nCounter CodeSet contained two types of built-
in controls: positive controls (spiked RNA at various concentra-
tions to assess the overall assay performance), and negative
controls (alien probes for background calculation). Data handling
and analysis was performed as described: background correction
consisted of the subtraction of the negative control average plus
two SD from the original counts. To select adequate normalization
genes from a series of candidates included in the CodeSet, their
relative stability was evaluated using geNorm-method [13]. For
the final normalization of the sample values the geometric mean of
the counts obtained for the selected normalization genes was
calculated and used as normalization factor.
In preliminary experiments one sample from normal PB, one
from normal BM, and one tumor sample were analyzed in
triplicates in several runs on the nCounter machine (Figure S2).
The ratio SD/mean for each value was ,0.5 for values between
50 and 106, and .0.5 to 1.1 for values between 1 and 50 for all
three triplicates. Similar low intra-assay variations have already
been observed by others [8]. We decided for the rest of our study
to perform each analysis for each sample only once.
The dynamic range and linearity of the assay were tested in
a dilution experiment (Figure S3).
Over a range of 2.5–3 log highly linear results were obtained, in
agreement with the results reported in the original description of
the technique [7].
Statistics
nCounter and flow cytometry results from a total of twenty-two
antigens were compared in eighty-six leukemia cases (forty-five
cases from Geneva and forty-one cases from other Swiss centers),
applying Pearson’s correlation.
Supporting Information
Figure S1 Heatmap for nCounter values (mRNA counts)
obtained for normal and leukemic samples, according
to table S7. Hierarchical supervised 2-way clustering was
performed with an Euclidean distance on the log2 of the signal
intensity. The values were centered around zero and color-coded
ranging from 26 to 6, according to the log2 value.
(TIF)
Figure S2 Technical reproducibility of the nCounter
assay. A tumor sample, a sample from a normal BM and
a normal peripheral blood sample were analyzed each in three
different runs with the nCounter. The graphs depict the
comparison between the different runs (log values), as well as the
corresponding correlation coefficients.
(TIF)
Figure S3 Linearity of the nCounter assay. A normal bone
marrow sample was diluted 1/3,1/9 and 1/27 and analyzed with
the nCounter. Shown are the results obtained for the twenty-five
most expressed antigens. Trendlines for two antigens are depicted.
(TIF)
Table S1 ‘‘CD mRNA phenotype’’ of normal peripheral
blood and bone marrow. Columns correspond to mean
nCounter values from peripheral blood (5) and bone marrow (11)
samples, ordered according to their expression in different cell
populations. SD = standard deviation.
(DOCX)
Table S2 Sample characteristics. Samples from Geneva
and from other Swiss centers (Aarau, Basel, Bellinzona, Bern,
Lausanne, Sion) were used for this study. *one plasmacytoid
dendritic cell leukemia (leukemic BPDC according to WHO
2008); one MDS (RCMD); one juvenile MM leukemia. Three
samples (1 from Geneva and 2 from other centers) were degraded
and not used for nCounter analysis.
(DOC)
Table S3 Correlation coefficients (Pearson) between
flow cytometry and nCounter. (A) Percentage of positive
cells and values from the nCounter analysis. (B) MFI values and
values from the nCounter analysis.
(DOC)
Table S4 A BM sample from a patient with B-ALL
containing 98% blasts was analyzed with the nCounter.
Samples were run undiluted, and diluted 1/2, 1/4, 1/8, 1/16 and
1/32 in normal BM. Genes, which were expressed by the leukemic
blasts, are highlighted in gray, as well as the dilutions at which
a distinction between leukemic and normal sample was possible
( = sensitivity of the assay for the detection of this gene).
(XLSX)
Table S5 CD protein and mRNA phenotype analysis of
forty-five leukemia patients with flow cytometry and
nCounter technology. The forty-five samples were ordered
according to the % of concordance (column E) between results
from nCounter technology and flow cytometry. Sample No 36 out
of the original forty-six samples was not analysed (degraded
material).
(DOCX)
Table S6 Concordance between Flow Cytometry and
nCounter values for forty-one different leukemia sam-
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ples obtained from other Swiss Centers. The forty-one
samples were ordered according to the % of concordance between
results from nCounter technology and flow cytometry. Two of the
original forty-three samples were not analysed (degraded material).
(XLSX)
Table S7 nCounter values (mRNA counts) for normal
and leukemic samples Samples (nBM, normal bone
marrow; nPB, normal peripheral blood; AML, LLA-B,
LLA-T) are ordered in columns and the genes tested in
lines. 88 genes were tested. For several genes values were not
obtained for all samples due to a restricted codeset used for the
analysis (ND; not done).
(XLS)
Table S8 Comparison of the data from the study by
Kern et al. with our own data. Correlation coefficients
(Spearman) are shown for twenty-two antigens. Legend: in bold
are correlation coefficients, which are higher in our study
compared to Kern et al.’s study (ND; not done).
(DOC)
Table S9 Reagents for flow cytometry and nCounter
analyses. A: Antibodies used for flow cytometric analysis. B:
Probes used in the nCounter analysis.
(DOC)
Table S10 Target sequences for probes used in the
nCounter analysis.
(XLSX)
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